| Next 10 |
Ad
BXRX News and Press Baudax Bio Inc.
-
2023-03-29 08:23:45 ET Draganfly DPRO -17% on proposed securities offering . SomaLogic SLGC -15% on Q4 earnings release . Shift Technologies SFT -15% on Q4 earnings release . Sharecare SHCR -12% on Q4 earnings release . Allarity Therapeu...
-
2023-03-28 08:24:33 ET Viking Therapeutics ( VKTX ) +46% jumps 39% on early-stage data for obesity candidate. Oscar Health ( OSCR ) +27% rises on CEO appointment. Intra-Cellular Therapies ( ITCI ) +15% Announces Positive Topline Results from S...
-
2023-03-27 12:09:23 ET Nano-cap biotech Baudax Bio ( NASDAQ: BXRX ) ended a six-day losing streak on Monday in reaction to promising data from a Phase 2 trial for its experimental neuromuscular blocking agent BX1000 in patients undergoing elective surgery. Citing a second ...
-
41 Subjects Meet Criteria for Good or Excellent Intubation Conditions at 60 Seconds Top Line Results Expected Late April/Early May MALVERN, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Nasdaq:BXRX) (the “Company”), a pharmaceutical company focused on innovat...
-
2023-03-17 08:33:13 ET Diebold Nixdorf DBD -28% on liquidity concerns . Sarepta Therapeutics SRPT -18% on FDA advisory meeting for its muscular dystrophy treatment . ThermoGenesis ( THMO ) -19% . First Republic Bank FRC -15% after suspending d...
-
2023-03-16 13:08:25 ET Gainers: Genelux ( GNLX ) +49% . PureCycle Technologies ( PCT ) +46% . Baudax Bio ( BXRX ) +35% . Lipella Pharmaceuticals ( LIPO ) +32% . Corbus Pharmaceuticals Holdings ( CRBP ) +27% . EverCommer...
-
Baudax Bio press release ( NASDAQ: BXRX ): Q4 GAAP EPS of -$12.33 misses by $2.57 . Revenue of $0.31M (-22.5% Y/Y). As of December 31, 2022, Baudax had cash and cash equivalents of $5.3 million. Shares +3.36% PM. For further details see: Baudax Bio GA...
-
Company Focuses on Development of Neuromuscular Blocking Agents Phase II Randomized Trial for BX1000 Initiated, Positive Interim Results Announced; Completion of Study Enrollment Expected Q1 2023, Top Line Results Expected Early Q2 2023 BX2000 Dose Escalation Study Progressing ...
-
InvestorPlace - Stock Market News, Stock Advice & Trading Tips What caused Baudax Bio (NASDAQ: BXRX ) stock to double earlier today? The catalyst was undoubtedly this morning’s announcement concerning a Phase 2 clinical trial of Baudax Bio’s novel product, BX1000. The r...
-
Baudax Bio ( NASDAQ: BXRX ) added ~70% pre-market Tuesday after announcing a positive outcome in its first interim analysis for Phase 2 trial for experimental neuromuscular blocking agent BX1000 in patients undergoing elective surgery. The trial is designed to evaluate the neuromu...
Stock Information
Baudax Bio Inc. Company Name:
BXRX Stock Symbol:
NYSE Market:
Get BXRX Alerts
News, Short Squeeze, Breakout and More Instantly...